Drug Search Results
More Filters [+]

Pracinostat

Alternative Names: pracinostat, sb939
Latest Update: 2024-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pracinostat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Myeloid Leukemia

Phase 2: Sarcoma|Myeloproliferative Disorders|Myelofibrosis|Thrombocythemia, Essential|Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Prostate Cancer|Polycythemia Vera

Phase 1: Tobacco Use Disorder|Healthy Volunteers|Leukemia|Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PRO 33922

P1

Completed

Acute Myeloid Leukemia

2021-05-05

MEI-011

P2

Terminated

Myelodysplastic Syndrome|Preleukemia

2020-12-01

24%

PRAN-16-52

P3

Terminated

Acute Myeloid Leukemia

2020-08-20

2016-004724-34

N/A

Terminated

Acute Myeloid Leukemia

2020-07-02

Recent News Events